This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Non-Small Cell Lung Carcinoma (NSCLC) Market

Market Insights on Non-Small Cell Lung Carcinoma (NSCLC) covering sales outlook, demand forecast & up-to-date key trends

Non-Small Cell Lung Carcinoma (NSCLC) Market by Type, Treatment, End User & Region – Forecast 2023–2033

Non-Small Cell Lung Carcinoma (NSCLC) Market Snapshot (2023-2033)

The global non-small cell lung carcinoma (NSCLC) market is expected to garner a market value of US$ 8.25 Billion in 2023 and is expected to accumulate a market value of US$ 21.40 Billion by registering a CAGR of 10% in the forecast period 2023-2033. Growth of the non-small cell lung carcinoma (NSCLC) market can be attributed to rising prevalence of NSCLC across the globe due to increasing air pollution and smoking habits amongst the people. The market for non-small cell lung carcinoma (NSCLC) registered a CAGR of 7.3% in the historical period 2017-2022.

The presence of a strong pipeline for non-small cell lung carcinoma is projected to propel the growth over the coming years. For instance, “fruquintinib (HMPL-013)”, a drug developed to treat advanced non-small cell lung carcinoma is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, development of such advanced treatments is expected to drive the market during the forecast period.

Report Attribute

Details

Estimated Base Year Value (2021)

US$ 7.5 Billion

Expected Market Value (2023)

US$ 8.25 Billion

Anticipated Forecast Value (2033)

US$ 21.4 Billion

Projected Growth Rate (2023-2033)

10% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2017-2022 Non-small Cell Lung Carcinoma (NSCLC) Market Demand Analysis vs. Forecast 2023-2033

According to market research and competitive intelligence provider Future Market Insights- the market for non-small cell lung carcinoma (NSCLC) reflected a value of 7.3% during the historical period, 2018- 2022.

Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to clinicaltrials.gov in July 2021, it was observed that more than 200 interventional studies were halted from March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.

Moreover, according to an article published in September 2020 titled "The impact of the COVID-19 pandemic on lung cancer patients," at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visit in April 2020, and 47 cases were finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments. Thus, the market for non-small cell lung carcinoma (NSCLC) is expected to register a CAGR of 10% in the forecast period 2023-2033.

Which are Some Prominent Drivers of Non-Small cell Lung Carcinoma (NSCLC) Market?

Smoking and tobacco consumption increasing number of patients suffering from non-small cell lung carcinoma

The American Cancer Society estimates that lung cancer is the one of the highest death-causing diseases across the world. Covid-19 significantly affected the non-small cell lung cancer-related clinical trials across the world. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of the national healthcare bodies and international healthcare systems worldwide.

The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients.

Approvals of Medication for Lung Carcinoma Propelling Market Growth

As per the statistics provided by the World Health Organization (WHO) updates from February 2022, 2.2 Billion patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung carcinoma patients resulted in the high demand for treating the patients.

Recent approvals of new drugs are expected to accelerate the market growth during the forecast period. For instance, In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the United States. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the Non-Small cell Lung Carcinoma (NSCLC) Market?

Longer Duration for approval of Medication hampering Growth of Market

The expensive nature of research and development of medication to treat patients is derailing the progress of the market. In addition, the financial burden added by the COVID-19 pandemic is playing a key role in hindering the growth of the market. Furthermore, the time taken for approval of drugs along with certain medications not being approved in spite of being in the clinical trial phase for a longer duration are hampering the overall growth of the non-small cell lung carcinoma market.

Region-Wise Insights

Research and Development Activities Favoring Growth of Non-Small Cell Lung Carcinoma Market in North America?

Launch of new drugs creating Favorable treatment for non-small cell lung carcinoma in North America

North America is expected to maintain its dominance during the forecast period and is one of the most lucrative regions for the NSCLC market. This is due to the presence of a strong pipeline and research activities undertaken by various industry players and academic institutions.

Thus, North America is expected to account for the largest share of all the regions in 2023. This is attributed to the entry of newer drugs, high investment by players, acceptance of costly drugs, and increased government funding for research and development activities. Owing to the aforementioned reasons, North America is expected to possess 40% market share for non-cell lung carcinoma market in 2023.

Large Patient Pool Creating Lucrative Opportunities for Non-Small Cell Lung Carcinoma Market in Asia Pacific?

Less stringent regulator framework opening doors for medication development in Asia Pacific

Asia Pacific is expected to be the second largest contributor in 2023 for non-small lung cell carcinoma market. This is owing to the presence of less stringent regulatory procedures for approval and a large patient pool. Japan and China are expected to contribute highest to the Asia Pacific region due to the availability of advanced drugs, developed economy, and a large patient pool.

Pricing pressure by the governments of European countries is likely to affect the market negatively during the forecast period. For instance, in October 2016, the National Institute for Health and Care Excellence (NICE) disapproved funding for Opdivo, as it did not meet the required cost-to-benefit ratio. Thus, Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Market Competition

Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.

  • In June 2021, AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
  • Pfizer, another key player in the non-small cell lung carcinoma is focusing on investing in research and development in manufacturing medications depending on the ailment. Thus, the company plans to examine its medication through clinical trial for receiving approval.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 8.25 Billion

Market Value in 2033

US$ 21.4 Billion

Growth Rate

CAGR of 10% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2017-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in USD Billion and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Type
  • Treatment
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Pfizer Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lily and Company
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Celgene Corp.
  • Sun Pharmaceutical Industries Ltd.

Customization

Available Upon Request

Key Segments Profiled in the Non-Small cell Lung Carcinoma (NSCLC) Industry Survey

Type:

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neruoendocrine Tumors

Treatment:

  • Chemotherapy
  • Targeted Therapy
    • Bevacizumab (Avastin)
    • Nectiumumbab (Portrazza)
    • Ramucirumab (Cyramza)
  • Immunotherapy
    • Nivolumab (Opdivo)
    • Atezolizumab (Tecentrig)
  • Others

End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa

Frequently Asked Questions

From 2018-2022, the non-small cell lung carcinoma (NSCLC) market grew at a CAGR of 7.3%

The global non-small cell lung carcinoma (NSCLC) market is expected to grow with a 10% CAGR during 2023-2033.

As of 2033, the non-small cell lung carcinoma (NSCLC) market is expected to reach US$ 21.40 Billion

North America is expected to possess 40% market share for non-small cell lung carcinoma (NSCLC) market in North America.

Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Type, 2018-2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type, 2023-2033

        5.3.1. Adenocarcinoma

        5.3.2. Squamous Cell Carcinoma

        5.3.3. Large Cell Carcinoma

        5.3.4. Large Cell Neuroendocrine Tumors

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2018-2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2023-2033

        6.3.1. Chemotherapy

        6.3.2. Targeted Therapy

            6.3.2.1. Bevacizumab (Avastin)

            6.3.2.2. Necitumumab (Portrazza)

            6.3.2.3. Ramucirumab (Cyramza)

        6.3.3. Immunotherapy

            6.3.3.1. Nivolumab (Opdivo)

            6.3.3.2. Atezolizumab (Tecentriq)

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023-2033

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User , 2018-2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User , 2023-2033

        7.3.1. Hospitals

        7.3.2. Homecare

        7.3.3. Specialty Clinics

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By End User , 2018-2022

    7.5. Absolute $ Opportunity Analysis By End User , 2023-2033

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia & Pacific

        8.3.5. East Asia

        8.3.6. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Treatment

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Treatment

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Treatment

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Treatment

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. By Treatment

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Treatment

        11.3.4. By End User

    11.4. Key Takeaways

12. South Asia & Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Australia

            12.2.1.6. New Zealand

            12.2.1.7. Rest of South Asia & Pacific

        12.2.2. By Type

        12.2.3. By Treatment

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Treatment

        12.3.4. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Type

        13.2.3. By Treatment

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Treatment

        13.3.4. By End User

    13.4. Key Takeaways

14. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Type

        14.2.3. By Treatment

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Treatment

        14.3.4. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Type

            15.1.2.2. By Treatment

            15.1.2.3. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Type

            15.2.2.2. By Treatment

            15.2.2.3. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Type

            15.3.2.2. By Treatment

            15.3.2.3. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Type

            15.4.2.2. By Treatment

            15.4.2.3. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Type

            15.5.2.2. By Treatment

            15.5.2.3. By End User

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Type

            15.6.2.2. By Treatment

            15.6.2.3. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Type

            15.7.2.2. By Treatment

            15.7.2.3. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Type

            15.8.2.2. By Treatment

            15.8.2.3. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Type

            15.9.2.2. By Treatment

            15.9.2.3. By End User

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Type

            15.10.2.2. By Treatment

            15.10.2.3. By End User

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Type

            15.11.2.2. By Treatment

            15.11.2.3. By End User

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Type

            15.12.2.2. By Treatment

            15.12.2.3. By End User

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Type

            15.13.2.2. By Treatment

            15.13.2.3. By End User

    15.14. Australia

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Type

            15.14.2.2. By Treatment

            15.14.2.3. By End User

    15.15. New Zealand

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Type

            15.15.2.2. By Treatment

            15.15.2.3. By End User

    15.16. China

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Type

            15.16.2.2. By Treatment

            15.16.2.3. By End User

    15.17. Japan

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Type

            15.17.2.2. By Treatment

            15.17.2.3. By End User

    15.18. South Korea

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Type

            15.18.2.2. By Treatment

            15.18.2.3. By End User

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Type

            15.19.2.2. By Treatment

            15.19.2.3. By End User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Type

            15.20.2.2. By Treatment

            15.20.2.3. By End User

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Type

            15.21.2.2. By Treatment

            15.21.2.3. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Type

        16.3.3. By Treatment

        16.3.4. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Pfizer Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. AstraZeneca plc

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. F. Hoffmann-La Roche Ltd.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Eli Lilly and Company

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Boehringer Ingelheim GMBH

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Novartis AG

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Bristol-Myers Squibb Company

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Merck & Co., Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Celgene Corp.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Sun Pharmaceutical Industries Ltd.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 3: Global Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 4: Global Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 6: North America Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 7: North America Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 8: North America Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 10: Latin America Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 11: Latin America Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 12: Latin America Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 14: Europe Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 15: Europe Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 16: Europe Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 17: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 18: South Asia & Pacific Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 19: South Asia & Pacific Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 20: South Asia & Pacific Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 21: East Asia Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 22: East Asia Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 23: East Asia Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 24: East Asia Market Value (US$ Mn) Forecast by End User , 2018-2033

Table 25: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 26: MEA Market Value (US$ Mn) Forecast by Type, 2018-2033

Table 27: MEA Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 28: MEA Market Value (US$ Mn) Forecast by End User , 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Type, 2023-2033

Figure 2: Global Market Value (US$ Mn) by Treatment, 2023-2033

Figure 3: Global Market Value (US$ Mn) by End User , 2023-2033

Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033

Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 8: Global Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 11: Global Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 14: Global Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 17: Global Market Attractiveness by Type, 2023-2033

Figure 18: Global Market Attractiveness by Treatment, 2023-2033

Figure 19: Global Market Attractiveness by End User , 2023-2033

Figure 20: Global Market Attractiveness by Region, 2023-2033

Figure 21: North America Market Value (US$ Mn) by Type, 2023-2033

Figure 22: North America Market Value (US$ Mn) by Treatment, 2023-2033

Figure 23: North America Market Value (US$ Mn) by End User , 2023-2033

Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033

Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 28: North America Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 31: North America Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 34: North America Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 37: North America Market Attractiveness by Type, 2023-2033

Figure 38: North America Market Attractiveness by Treatment, 2023-2033

Figure 39: North America Market Attractiveness by End User , 2023-2033

Figure 40: North America Market Attractiveness by Country, 2023-2033

Figure 41: Latin America Market Value (US$ Mn) by Type, 2023-2033

Figure 42: Latin America Market Value (US$ Mn) by Treatment, 2023-2033

Figure 43: Latin America Market Value (US$ Mn) by End User , 2023-2033

Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033

Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 48: Latin America Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 51: Latin America Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 54: Latin America Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 57: Latin America Market Attractiveness by Type, 2023-2033

Figure 58: Latin America Market Attractiveness by Treatment, 2023-2033

Figure 59: Latin America Market Attractiveness by End User , 2023-2033

Figure 60: Latin America Market Attractiveness by Country, 2023-2033

Figure 61: Europe Market Value (US$ Mn) by Type, 2023-2033

Figure 62: Europe Market Value (US$ Mn) by Treatment, 2023-2033

Figure 63: Europe Market Value (US$ Mn) by End User , 2023-2033

Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033

Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 68: Europe Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 71: Europe Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 74: Europe Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 77: Europe Market Attractiveness by Type, 2023-2033

Figure 78: Europe Market Attractiveness by Treatment, 2023-2033

Figure 79: Europe Market Attractiveness by End User , 2023-2033

Figure 80: Europe Market Attractiveness by Country, 2023-2033

Figure 81: South Asia & Pacific Market Value (US$ Mn) by Type, 2023-2033

Figure 82: South Asia & Pacific Market Value (US$ Mn) by Treatment, 2023-2033

Figure 83: South Asia & Pacific Market Value (US$ Mn) by End User , 2023-2033

Figure 84: South Asia & Pacific Market Value (US$ Mn) by Country, 2023-2033

Figure 85: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 86: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 87: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 88: South Asia & Pacific Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 89: South Asia & Pacific Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 90: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 91: South Asia & Pacific Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 92: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 93: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 94: South Asia & Pacific Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 95: South Asia & Pacific Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 96: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 97: South Asia & Pacific Market Attractiveness by Type, 2023-2033

Figure 98: South Asia & Pacific Market Attractiveness by Treatment, 2023-2033

Figure 99: South Asia & Pacific Market Attractiveness by End User , 2023-2033

Figure 100: South Asia & Pacific Market Attractiveness by Country, 2023-2033

Figure 101: East Asia Market Value (US$ Mn) by Type, 2023-2033

Figure 102: East Asia Market Value (US$ Mn) by Treatment, 2023-2033

Figure 103: East Asia Market Value (US$ Mn) by End User , 2023-2033

Figure 104: East Asia Market Value (US$ Mn) by Country, 2023-2033

Figure 105: East Asia Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 108: East Asia Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 111: East Asia Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 114: East Asia Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 117: East Asia Market Attractiveness by Type, 2023-2033

Figure 118: East Asia Market Attractiveness by Treatment, 2023-2033

Figure 119: East Asia Market Attractiveness by End User , 2023-2033

Figure 120: East Asia Market Attractiveness by Country, 2023-2033

Figure 121: MEA Market Value (US$ Mn) by Type, 2023-2033

Figure 122: MEA Market Value (US$ Mn) by Treatment, 2023-2033

Figure 123: MEA Market Value (US$ Mn) by End User , 2023-2033

Figure 124: MEA Market Value (US$ Mn) by Country, 2023-2033

Figure 125: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 128: MEA Market Value (US$ Mn) Analysis by Type, 2018-2033

Figure 129: MEA Market Value Share (%) and BPS Analysis by Type, 2023-2033

Figure 130: MEA Market Y-o-Y Growth (%) Projections by Type, 2023-2033

Figure 131: MEA Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 132: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 133: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 134: MEA Market Value (US$ Mn) Analysis by End User , 2018-2033

Figure 135: MEA Market Value Share (%) and BPS Analysis by End User , 2023-2033

Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User , 2023-2033

Figure 137: MEA Market Attractiveness by Type, 2023-2033

Figure 138: MEA Market Attractiveness by Treatment, 2023-2033

Figure 139: MEA Market Attractiveness by End User , 2023-2033

Figure 140: MEA Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Lung Biopsy Systems Market

Published : April 2019

Healthcare

Lung Disease Therapeutics Market

Published : July 2017

Healthcare

Lung Cancer Therapeutics Market

Published : February 2022

Healthcare

Lung Cancer Surgery Market

Published : January 2022

Google translate

Non-Small Cell Lung Carcinoma (NSCLC) Market